- Home
- WSFS vs CPRX Comparison
WSFS vs CPRX Comparison
Compare WSFS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSFS | CPRX |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 1995 | 2006 |
Fundamental Metrics
Financial Performance| Metric | WSFS | CPRX |
|---|---|---|
| Price | $62.90 | $23.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $69.80 | $35.00 |
| AVG Volume (30 Days) | 310.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | 15.42 | ★ 28.24 |
| EPS | ★ 5.09 | 1.68 |
| Revenue | ★ $963,949,000.00 | $119,072,803.00 |
| Revenue This Year | N/A | $8.00 |
| Revenue Next Year | $3.51 | $9.77 |
| P/E Ratio | ★ $12.28 | $14.53 |
| Revenue Growth | ★ 50.18 | 16.39 |
| 52 Week Low | $42.44 | $19.05 |
| 52 Week High | $71.32 | $26.56 |
Technical Indicators
Market Signals| Indicator | WSFS | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 43.93 |
| Support Level | $55.05 | $22.46 |
| Resistance Level | $71.32 | $24.86 |
| Average True Range (ATR) | 1.90 | 0.99 |
| MACD | -0.57 | -0.05 |
| Stochastic Oscillator | 32.01 | 38.29 |
Price Performance
Historical ComparisonAbout WSFS WSFS Financial Corporation
WSFS Financial Corp is a savings and loan holding company. The company operates in three segments: WSFS Bank provides loans and leases and other financial products to commercial and consumer customers. Cash Connect segment provides ATM vault cash, smart safe, and other cash logistics services; and Wealth Management provides a broad array of planning and advisor services, investment management, personal and institutional trust services, and credit and deposit products to individuals, corporate, and institutional clients. Majority revenue is generated from WSFS Bank segment.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.